Skip to main content
Erschienen in: Sports Medicine 1/2015

01.01.2015 | Review Article

Prevalence of Doping Use in Elite Sports: A Review of Numbers and Methods

verfasst von: Olivier de Hon, Harm Kuipers, Maarten van Bottenburg

Erschienen in: Sports Medicine | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of doping in elite sports is relevant for all those involved in sports, particularly for evaluating anti-doping policy measures. Remarkably, few scientific articles have addressed this subject so far, and the last review dates back to 1997. As a consequence, the true prevalence of doping in elite sports is unknown. Even though it is virtually impossible to uncover the exact prevalence of a prohibited activity such as doping, various methods are available to uncover parts of this particular problem, which enables the circumvention (to a certain degree) of the issues of truthfulness, definition problems and the limits of pharmacological evidence. This review outlines the various methods that exist and presents the scarce data available in this area. It is concluded that a combination of questionnaires using the Randomised Response Technique and models of biological parameters is able to provide the statistical possibilities to reveal accurate estimates of this often undisclosed practice. Data gathered in this way yield an estimation of 14–39 % of current adult elite athletes who intentionally used doping. These period prevalences have been found in specific sub-groups of elite athletes, and the available data suggest that the prevalence of doping is considerably different between sub-groups with varying types of sport, levels and nationalities. The above-mentioned figure of 14–39 % is likely to be a more accurate reflection of the prevalence of intentional doping in elite sports than that provided by doping control test results (estimate of doping: 1–2 % annually) or questionnaire-based research (estimations between 1 and 70 % depending on sport, level and exact definitions of intent and doping). In the future, analytical science may play a more important role in this topic if it may become feasible to detect very low concentrations of prohibited substances in sewage systems downstream of major sporting events. However, it is clear that current doping control test results show a distinct underestimation of true doping prevalence. It does not seem feasible to distil better estimates of the prevalence of doping based on performance indicators or ego documents because of the various existing effects that influence athletic performance. Such information can only be used as extra information to augment the accuracy of prevalence rates that have been found by using other techniques. True doping prevalence studies have been scarce in elite sports so far. With the correct application of the available scientific methods, preferably using harmonised definitions of the terms ‘doping’ and ‘elite sports’, more information on this topic may be gathered in a relatively short time. This would assist anti-doping professionals in the future in order to evaluate the effects of possible anti-doping measures, and better anti-doping policies would serve athletes who compete without doping. The existing anti-doping measures seriously impact the lives of elite athletes and their immediate entourage, which imposes a moral burden to evaluate these measures in the best possible way.
Literatur
1.
Zurück zum Zitat USADA. U.S. postal service pro cycling team investigation. Colorado Springs, United States of America: United States Anti-Doping Agency; 2012. USADA. U.S. postal service pro cycling team investigation. Colorado Springs, United States of America: United States Anti-Doping Agency; 2012.
2.
Zurück zum Zitat Sorgdrager W, van Bottenburg M, Goedhart E. Joining or Quitting [Original Title: ‘Meedoen of Stoppen’]. Arnhem, The Netherlands; 2013. Sorgdrager W, van Bottenburg M, Goedhart E. Joining or Quitting [Original Title: ‘Meedoen of Stoppen’]. Arnhem, The Netherlands; 2013.
4.
Zurück zum Zitat Laure P. Epidemiologic approach of doping in sport. A review. J Sports Med Phys Fitness. 1997;37(3):218–24.PubMed Laure P. Epidemiologic approach of doping in sport. A review. J Sports Med Phys Fitness. 1997;37(3):218–24.PubMed
5.
Zurück zum Zitat Hatton CK. Beyond sports-doping headlines: the science of laboratory tests for performance-enhancing drugs. Pediatr Clin North Am. 2007;54(4):713–33 (xi).PubMedCrossRef Hatton CK. Beyond sports-doping headlines: the science of laboratory tests for performance-enhancing drugs. Pediatr Clin North Am. 2007;54(4):713–33 (xi).PubMedCrossRef
6.
Zurück zum Zitat Lentillon-Kaestner V, Ohl F. Can we measure accurately the prevalence of doping? Scand J Med Sci Sports. 2011;21(6):e132–42.PubMedCrossRef Lentillon-Kaestner V, Ohl F. Can we measure accurately the prevalence of doping? Scand J Med Sci Sports. 2011;21(6):e132–42.PubMedCrossRef
7.
Zurück zum Zitat D’Angelo C, Tamburrini C. Addict to win? A different approach to doping. J Med Ethics. 2010;36(11):700–7.PubMedCrossRef D’Angelo C, Tamburrini C. Addict to win? A different approach to doping. J Med Ethics. 2010;36(11):700–7.PubMedCrossRef
8.
Zurück zum Zitat Kayser B, Mauron A, Miah A. Viewpoint: legalisation of performance-enhancing drugs. Lancet. 2005;366(Suppl 1):S21.PubMedCrossRef Kayser B, Mauron A, Miah A. Viewpoint: legalisation of performance-enhancing drugs. Lancet. 2005;366(Suppl 1):S21.PubMedCrossRef
10.
Zurück zum Zitat McNamee MJ, Tarasti L. Juridical and ethical peculiarities in doping policy. J Med Ethics. 2010;36(3):165–9.PubMedCrossRef McNamee MJ, Tarasti L. Juridical and ethical peculiarities in doping policy. J Med Ethics. 2010;36(3):165–9.PubMedCrossRef
12.
Zurück zum Zitat Berning JM, Adams KJ, Stamford BA. Anabolic steroid usage in athletics: facts, fiction, and public relations. J Strength Cond Res. 2004;18(4):908–17.PubMed Berning JM, Adams KJ, Stamford BA. Anabolic steroid usage in athletics: facts, fiction, and public relations. J Strength Cond Res. 2004;18(4):908–17.PubMed
13.
Zurück zum Zitat Jenkins PJ. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res. 2001;11(Suppl A):S71–7.PubMedCrossRef Jenkins PJ. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res. 2001;11(Suppl A):S71–7.PubMedCrossRef
14.
Zurück zum Zitat WADA. The 2013 Prohibited List International Standard. Montreal, Canada: World Anti-Doping Agency; 2012. WADA. The 2013 Prohibited List International Standard. Montreal, Canada: World Anti-Doping Agency; 2012.
16.
Zurück zum Zitat Bowers LD. The analytical chemistry of drug monitoring in athletes. Annu Rev Anal Chem (Palo Alto Calif). 2009;2:485–507.CrossRef Bowers LD. The analytical chemistry of drug monitoring in athletes. Annu Rev Anal Chem (Palo Alto Calif). 2009;2:485–507.CrossRef
17.
Zurück zum Zitat Catlin DH, Fitch KD, Ljungqvist A. Medicine and science in the fight against doping in sport. J Intern Med. 2008;264(2):99–114.PubMedCrossRef Catlin DH, Fitch KD, Ljungqvist A. Medicine and science in the fight against doping in sport. J Intern Med. 2008;264(2):99–114.PubMedCrossRef
18.
Zurück zum Zitat Lentillon-Kaestner V. The development of doping use in high-level cycling: from team-organized doping to advances in the fight against doping. Scand J Med Sci Sports. 2013;23(2):189–97.PubMedCrossRef Lentillon-Kaestner V. The development of doping use in high-level cycling: from team-organized doping to advances in the fight against doping. Scand J Med Sci Sports. 2013;23(2):189–97.PubMedCrossRef
19.
Zurück zum Zitat Voet W. Prikken en slikken [original title: Massacre a la chaine]. Roeselare: Roularta Books NV; 1999. Voet W. Prikken en slikken [original title: Massacre a la chaine]. Roeselare: Roularta Books NV; 1999.
22.
Zurück zum Zitat Le Ressiot D. Mensonge Armstrong [The Armstrong Lie]. L’Equipe. 2005;2005:23. Le Ressiot D. Mensonge Armstrong [The Armstrong Lie]. L’Equipe. 2005;2005:23.
23.
Zurück zum Zitat Verroken M. Ethical aspects and the prevalence of hormone abuse in sport. J Endocrinol. 2001;170(1):49–54.PubMedCrossRef Verroken M. Ethical aspects and the prevalence of hormone abuse in sport. J Endocrinol. 2001;170(1):49–54.PubMedCrossRef
24.
Zurück zum Zitat Bahr R, Tjornhom M. Prevalence of doping in sports: doping control in Norway, 1977–1995. Clin J Sport Med. 1998;8(1):32–7.PubMedCrossRef Bahr R, Tjornhom M. Prevalence of doping in sports: doping control in Norway, 1977–1995. Clin J Sport Med. 1998;8(1):32–7.PubMedCrossRef
25.
Zurück zum Zitat Palmer W, Taylor S, Wingate A. Adverse analyzing—a European study of anti doping organization reporting practices and the efficacy of drug testing athletes. Switzerland: UNI Global Union; 2011. Palmer W, Taylor S, Wingate A. Adverse analyzing—a European study of anti doping organization reporting practices and the efficacy of drug testing athletes. Switzerland: UNI Global Union; 2011.
26.
Zurück zum Zitat Strano Rossi S, Botre F. Prevalence of illicit drug use among the Italian athlete population with special attention on drugs of abuse: a 10-year review. J Sports Sci. 2011;29(5):471–6.PubMedCrossRef Strano Rossi S, Botre F. Prevalence of illicit drug use among the Italian athlete population with special attention on drugs of abuse: a 10-year review. J Sports Sci. 2011;29(5):471–6.PubMedCrossRef
27.
Zurück zum Zitat van der Merwe PJ, Kruger HS. Drugs in sport—results of the past 6 years of dope testing in South Africa. S Afr Med J. 1992;82(3):151–3.PubMed van der Merwe PJ, Kruger HS. Drugs in sport—results of the past 6 years of dope testing in South Africa. S Afr Med J. 1992;82(3):151–3.PubMed
29.
Zurück zum Zitat Pluim B. A doping sinner is not always a cheat. Br J Sports Med. 2008;42(7):549–50.PubMed Pluim B. A doping sinner is not always a cheat. Br J Sports Med. 2008;42(7):549–50.PubMed
30.
Zurück zum Zitat Zorzoli M, Rossi F. Implementation of the biological passport: the experience of the International Cycling Union. Drug Test Anal. 2010;2(11–12):542–7.PubMedCrossRef Zorzoli M, Rossi F. Implementation of the biological passport: the experience of the International Cycling Union. Drug Test Anal. 2010;2(11–12):542–7.PubMedCrossRef
31.
Zurück zum Zitat Videman T, Lereim I, Hemmingsson P, et al. Changes in hemoglobin values in elite cross-country skiers from 1987–1999. Scand J Med Sci Sports. 2000;10(2):98–102.PubMedCrossRef Videman T, Lereim I, Hemmingsson P, et al. Changes in hemoglobin values in elite cross-country skiers from 1987–1999. Scand J Med Sci Sports. 2000;10(2):98–102.PubMedCrossRef
32.
Zurück zum Zitat Manfredini F, Carrabre JE, Litmanen H, et al. Blood tests and fair competition: the biathlon experience. Int J Sports Med. 2003;24(5):352–8.PubMedCrossRef Manfredini F, Carrabre JE, Litmanen H, et al. Blood tests and fair competition: the biathlon experience. Int J Sports Med. 2003;24(5):352–8.PubMedCrossRef
33.
Zurück zum Zitat Sottas PE, Robinson N, Saugy M, et al. A forensic approach to the interpretation of blood doping markers. Law Probab Risk. 2008;7(3):191–210.CrossRef Sottas PE, Robinson N, Saugy M, et al. A forensic approach to the interpretation of blood doping markers. Law Probab Risk. 2008;7(3):191–210.CrossRef
34.
Zurück zum Zitat Sottas PE, Robinson N, Saugy M. The athlete’s biological passport and indirect markers of blood doping. Handb Exp Pharmacol. 2010;195:305–26.PubMedCrossRef Sottas PE, Robinson N, Saugy M. The athlete’s biological passport and indirect markers of blood doping. Handb Exp Pharmacol. 2010;195:305–26.PubMedCrossRef
35.
Zurück zum Zitat Sottas PE, Saudan C, Saugy M. Doping: a paradigm shift has taken place in testing. Nature. 2008;455(7210):166.PubMedCrossRef Sottas PE, Saudan C, Saugy M. Doping: a paradigm shift has taken place in testing. Nature. 2008;455(7210):166.PubMedCrossRef
36.
Zurück zum Zitat Sottas PE, Robinson N, Fischetto G, et al. Prevalence of blood doping in samples collected from elite track and field athletes. Clin Chem. 2011;57(5):762–9.PubMedCrossRef Sottas PE, Robinson N, Fischetto G, et al. Prevalence of blood doping in samples collected from elite track and field athletes. Clin Chem. 2011;57(5):762–9.PubMedCrossRef
37.
Zurück zum Zitat Vouillamoz M, Thom C, Grisdale R, et al. Anti-doping testing at the 2008 European football championship. Drug Test Anal. 2009;1(11–12):485–93.PubMedCrossRef Vouillamoz M, Thom C, Grisdale R, et al. Anti-doping testing at the 2008 European football championship. Drug Test Anal. 2009;1(11–12):485–93.PubMedCrossRef
38.
Zurück zum Zitat Stray-Gundersen J, Videman T, Penttila I, et al. Abnormal hematologic profiles in elite cross-country skiers: blood doping or? Clin J Sport Med. 2003;13(3):132–7.PubMedCrossRef Stray-Gundersen J, Videman T, Penttila I, et al. Abnormal hematologic profiles in elite cross-country skiers: blood doping or? Clin J Sport Med. 2003;13(3):132–7.PubMedCrossRef
39.
Zurück zum Zitat Kuipers H, Moran J, Dubravcic-Simunjak S, et al. Hemoglobin level in elite speed skaters from 2000 up to 2005, and its relationship with competitive results. Int J Sports Med. 2007;28(1):16–20.PubMedCrossRef Kuipers H, Moran J, Dubravcic-Simunjak S, et al. Hemoglobin level in elite speed skaters from 2000 up to 2005, and its relationship with competitive results. Int J Sports Med. 2007;28(1):16–20.PubMedCrossRef
40.
Zurück zum Zitat Kuipers H, Moran J, Mitchell DW, et al. Hemoglobin levels and athletic performance in elite speed skaters during the Olympic season 2006. Clin J Sport Med. 2007;17(2):135–9.PubMedCrossRef Kuipers H, Moran J, Mitchell DW, et al. Hemoglobin levels and athletic performance in elite speed skaters during the Olympic season 2006. Clin J Sport Med. 2007;17(2):135–9.PubMedCrossRef
41.
Zurück zum Zitat Sottas PE, Saudan C, Schweizer C, et al. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int. 2008;174(2–3):166–72.PubMedCrossRef Sottas PE, Saudan C, Schweizer C, et al. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int. 2008;174(2–3):166–72.PubMedCrossRef
42.
Zurück zum Zitat Schumacher YO, Saugy M, Pottgiesser T, et al. Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. Drug Test Anal. 2012;4:846–53.PubMedCrossRef Schumacher YO, Saugy M, Pottgiesser T, et al. Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. Drug Test Anal. 2012;4:846–53.PubMedCrossRef
43.
Zurück zum Zitat Schroder HF, Gebhardt W, Thevis M. Anabolic, doping, and lifestyle drugs, and selected metabolites in wastewater-detection, quantification, and behaviour monitored by high-resolution MS and MS(n) before and after sewage treatment. Anal Bioanal Chem. 2010;398(3):1207–29.PubMedCrossRef Schroder HF, Gebhardt W, Thevis M. Anabolic, doping, and lifestyle drugs, and selected metabolites in wastewater-detection, quantification, and behaviour monitored by high-resolution MS and MS(n) before and after sewage treatment. Anal Bioanal Chem. 2010;398(3):1207–29.PubMedCrossRef
44.
Zurück zum Zitat Reid MJ, Langford KH, Grung M, et al. Estimation of cocaine consumption in the community: a critical comparison of the results from three complimentary techniques. BMJ Open. 2012;2(6). Reid MJ, Langford KH, Grung M, et al. Estimation of cocaine consumption in the community: a critical comparison of the results from three complimentary techniques. BMJ Open. 2012;2(6).
45.
Zurück zum Zitat Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol. 2004;4(6):614–20.PubMedCrossRef Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol. 2004;4(6):614–20.PubMedCrossRef
46.
Zurück zum Zitat Bahrke MS, Yesalis CE, Kopstein AN, et al. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000;29(6):397–405.PubMedCrossRef Bahrke MS, Yesalis CE, Kopstein AN, et al. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000;29(6):397–405.PubMedCrossRef
47.
Zurück zum Zitat Castillo EM, Comstock RD. Prevalence of use of performance-enhancing substances among United States adolescents. Pediatr Clin North Am. 2007;54(4):663–75 (ix–x).PubMedCrossRef Castillo EM, Comstock RD. Prevalence of use of performance-enhancing substances among United States adolescents. Pediatr Clin North Am. 2007;54(4):663–75 (ix–x).PubMedCrossRef
48.
Zurück zum Zitat Kindlundh AM, Isacson DG, Berglund L, et al. Doping among high school students in Uppsala, Sweden: a presentation of the attitudes, distribution, side effects, and extent of use. Scand J Soc Med. 1998;26(1):71–4.PubMed Kindlundh AM, Isacson DG, Berglund L, et al. Doping among high school students in Uppsala, Sweden: a presentation of the attitudes, distribution, side effects, and extent of use. Scand J Soc Med. 1998;26(1):71–4.PubMed
49.
50.
Zurück zum Zitat Sjoqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371(9627):1872–82.PubMedCrossRef Sjoqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371(9627):1872–82.PubMedCrossRef
51.
Zurück zum Zitat van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117–23.PubMedCrossRef van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117–23.PubMedCrossRef
52.
Zurück zum Zitat vandenBerg P, Neumark-Sztainer D, Cafri G, et al. Steroid use among adolescents: longitudinal findings from Project EAT. Pediatrics. 2007;119(3):476–86.PubMedCrossRef vandenBerg P, Neumark-Sztainer D, Cafri G, et al. Steroid use among adolescents: longitudinal findings from Project EAT. Pediatrics. 2007;119(3):476–86.PubMedCrossRef
53.
Zurück zum Zitat Nilsson S, Baigi A, Marklund B, et al. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health. 2001;11(2):195–7.PubMedCrossRef Nilsson S, Baigi A, Marklund B, et al. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health. 2001;11(2):195–7.PubMedCrossRef
54.
Zurück zum Zitat Terney R, McLain LG. The use of anabolic steroids in high school students. Am J Dis Child. 1990;144(1):99–103.PubMed Terney R, McLain LG. The use of anabolic steroids in high school students. Am J Dis Child. 1990;144(1):99–103.PubMed
55.
Zurück zum Zitat Papadopoulos FC, Skalkidis I, Parkkari J, et al. Doping use among tertiary education students in six developed countries. Eur J Epidemiol. 2006;21(4):307–13.PubMedCrossRef Papadopoulos FC, Skalkidis I, Parkkari J, et al. Doping use among tertiary education students in six developed countries. Eur J Epidemiol. 2006;21(4):307–13.PubMedCrossRef
56.
Zurück zum Zitat Wanjek B, Rosendahl J, Strauss B, et al. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med. 2007;28(4):346–53.PubMedCrossRef Wanjek B, Rosendahl J, Strauss B, et al. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med. 2007;28(4):346–53.PubMedCrossRef
57.
Zurück zum Zitat Windsor R, Dumitru D. Prevalence of anabolic steroid use by male and female adolescents. Med Sci Sports Exerc. 1989;21(5):494–7.PubMedCrossRef Windsor R, Dumitru D. Prevalence of anabolic steroid use by male and female adolescents. Med Sci Sports Exerc. 1989;21(5):494–7.PubMedCrossRef
58.
Zurück zum Zitat Yesalis CE, Bahrke MS. Anabolic-androgenic steroids. Current issues. Sports Med. 1995;19(5):326–40.PubMedCrossRef Yesalis CE, Bahrke MS. Anabolic-androgenic steroids. Current issues. Sports Med. 1995;19(5):326–40.PubMedCrossRef
59.
Zurück zum Zitat Thevis M, Sauer M, Geyer H, et al. Determination of the prevalence of anabolic steroids, stimulants, and selected drugs subject to doping controls among elite sport students using analytical chemistry. J Sports Sci. 2008;26(10):1059–65.PubMedCrossRef Thevis M, Sauer M, Geyer H, et al. Determination of the prevalence of anabolic steroids, stimulants, and selected drugs subject to doping controls among elite sport students using analytical chemistry. J Sports Sci. 2008;26(10):1059–65.PubMedCrossRef
60.
Zurück zum Zitat Melnik BC. Androgen abuse in the community. Curr Opin Endocrinol Diabetes Obes. 2009;16(3):218–23.PubMedCrossRef Melnik BC. Androgen abuse in the community. Curr Opin Endocrinol Diabetes Obes. 2009;16(3):218–23.PubMedCrossRef
62.
Zurück zum Zitat Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: a regional study. Eur J Intern Med. 2006;17(7):479–84.PubMedCrossRef Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: a regional study. Eur J Intern Med. 2006;17(7):479–84.PubMedCrossRef
63.
Zurück zum Zitat Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534–42.PubMedCrossRef Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534–42.PubMedCrossRef
64.
Zurück zum Zitat Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction. 2002;97(2):195–203.PubMedCrossRef Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction. 2002;97(2):195–203.PubMedCrossRef
65.
Zurück zum Zitat Da Silva PR, Machado LC Jr, Figueiredo VC, et al. Prevalence of the use of anabolic agents among strength training apprentices in Porto Alegre, RS. Arq Bras Endocrinol Metabol. 2007;51(1):104–10.PubMedCrossRef Da Silva PR, Machado LC Jr, Figueiredo VC, et al. Prevalence of the use of anabolic agents among strength training apprentices in Porto Alegre, RS. Arq Bras Endocrinol Metabol. 2007;51(1):104–10.PubMedCrossRef
66.
Zurück zum Zitat Graham MR, Davies B, Grace FM, et al. Anabolic steroid use: patterns of use and detection of doping. Sports Med. 2008;38(6):505–25.PubMedCrossRef Graham MR, Davies B, Grace FM, et al. Anabolic steroid use: patterns of use and detection of doping. Sports Med. 2008;38(6):505–25.PubMedCrossRef
67.
Zurück zum Zitat Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend. 2006;81(1):11–9.PubMedCrossRef Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend. 2006;81(1):11–9.PubMedCrossRef
68.
Zurück zum Zitat Tricker R, O’Neill MR, Cook D. The incidence of anabolic steroid use among competitive bodybuilders. J Drug Educ. 1989;19(4):313–25.PubMedCrossRef Tricker R, O’Neill MR, Cook D. The incidence of anabolic steroid use among competitive bodybuilders. J Drug Educ. 1989;19(4):313–25.PubMedCrossRef
69.
Zurück zum Zitat Kanayama G, Gruber AJ, Pope HG Jr, et al. Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem? Psychother Psychosom. 2001;70(3):137–40.PubMedCrossRef Kanayama G, Gruber AJ, Pope HG Jr, et al. Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem? Psychother Psychosom. 2001;70(3):137–40.PubMedCrossRef
70.
71.
Zurück zum Zitat Petroczi A, Uvacsek M, Nepusz T, et al. Incongruence in doping related attitudes, beliefs and opinions in the context of discordant behavioural data: in which measure do we trust? PLoS One. 2011;6(4):e18804.PubMedCentralPubMedCrossRef Petroczi A, Uvacsek M, Nepusz T, et al. Incongruence in doping related attitudes, beliefs and opinions in the context of discordant behavioural data: in which measure do we trust? PLoS One. 2011;6(4):e18804.PubMedCentralPubMedCrossRef
72.
Zurück zum Zitat Striegel H, Ulrich R, Simon P. Randomized response estimates for doping and illicit drug use in elite athletes. Drug Alcohol Depend. 2010;106(2–3):230–2.PubMedCrossRef Striegel H, Ulrich R, Simon P. Randomized response estimates for doping and illicit drug use in elite athletes. Drug Alcohol Depend. 2010;106(2–3):230–2.PubMedCrossRef
73.
Zurück zum Zitat Secades-Villa R, Fernandez-Hermida JR. The validity of self-reports in a follow-up study with drug addicts. Addict Behav. 2003;28(6):1175–82.PubMedCrossRef Secades-Villa R, Fernandez-Hermida JR. The validity of self-reports in a follow-up study with drug addicts. Addict Behav. 2003;28(6):1175–82.PubMedCrossRef
74.
Zurück zum Zitat Stone AL, Latimer WW. Adolescent substance use assessment: concordance between tools using self-administered and interview formats. Subst Use Misuse. 2005;40(12):1865–74.PubMedCrossRef Stone AL, Latimer WW. Adolescent substance use assessment: concordance between tools using self-administered and interview formats. Subst Use Misuse. 2005;40(12):1865–74.PubMedCrossRef
75.
Zurück zum Zitat Goldman B, Bush P, Klatz R. Death in the locker room. United States: Icarus Press; 1984. Goldman B, Bush P, Klatz R. Death in the locker room. United States: Icarus Press; 1984.
76.
Zurück zum Zitat Connor J, Woolf J, Mazanov J. Would they dope? Revisiting the Goldman dilemma. Br J Sports Med. 2013;47(11):697–700.PubMedCrossRef Connor J, Woolf J, Mazanov J. Would they dope? Revisiting the Goldman dilemma. Br J Sports Med. 2013;47(11):697–700.PubMedCrossRef
77.
Zurück zum Zitat Lensvelt-Mulders G, Hox J, Van der Heijden P, et al. Meta-analysis of randomized response research: thirty-five years of validation. Sociol Methods Res. 2005;33:319–48.CrossRef Lensvelt-Mulders G, Hox J, Van der Heijden P, et al. Meta-analysis of randomized response research: thirty-five years of validation. Sociol Methods Res. 2005;33:319–48.CrossRef
78.
Zurück zum Zitat Lensvelt-Mulders G, Hox J, Van der Heijden P. How to improve the efficiency of randomized response designs. Qual Quant. 2005;39:253–65.CrossRef Lensvelt-Mulders G, Hox J, Van der Heijden P. How to improve the efficiency of randomized response designs. Qual Quant. 2005;39:253–65.CrossRef
79.
Zurück zum Zitat Pitsch W, Emrich E, Klein M. Doping in elite sports in Germany: results of a www survey. Eur J Sport Soc. 2007;4(2):89–102. Pitsch W, Emrich E, Klein M. Doping in elite sports in Germany: results of a www survey. Eur J Sport Soc. 2007;4(2):89–102.
80.
Zurück zum Zitat Stubbe JH, Chorus AMJ, Frank LE, et al. Prevalence of use of performance enhancing drugs by fitness center members. Drug Test Anal. 2013;6(5):434–8.PubMed Stubbe JH, Chorus AMJ, Frank LE, et al. Prevalence of use of performance enhancing drugs by fitness center members. Drug Test Anal. 2013;6(5):434–8.PubMed
81.
Zurück zum Zitat Simon P, Striegel H, Aust F, et al. Doping in fitness sports: estimated number of unreported cases and individual probability of doping. Addiction. 2006;101(11):1640–4.PubMedCrossRef Simon P, Striegel H, Aust F, et al. Doping in fitness sports: estimated number of unreported cases and individual probability of doping. Addiction. 2006;101(11):1640–4.PubMedCrossRef
82.
Zurück zum Zitat Seiler S, Beneke R, Halson SL, et al. Is doping-free sport a Utopia? Int J Sports Physiol Perform. 2013;8(1):1–3.PubMed Seiler S, Beneke R, Halson SL, et al. Is doping-free sport a Utopia? Int J Sports Physiol Perform. 2013;8(1):1–3.PubMed
83.
Zurück zum Zitat Zhong W, Wu H, Li L. Olympics: some facts about Ye Shiwen’s swim. Nature. 2012;488(7412):459.PubMedCrossRef Zhong W, Wu H, Li L. Olympics: some facts about Ye Shiwen’s swim. Nature. 2012;488(7412):459.PubMedCrossRef
87.
Zurück zum Zitat Noakes TD. Tainted glory—doping and athletic performance. N Engl J Med. 2004;351(9):847–9.PubMedCrossRef Noakes TD. Tainted glory—doping and athletic performance. N Engl J Med. 2004;351(9):847–9.PubMedCrossRef
88.
Zurück zum Zitat Seiler S, De Koning JJ, Foster C. The fall and rise of the gender difference in elite anaerobic performance 1952–2006. Med Sci Sports Exerc. 2007;39(3):534–40.PubMedCrossRef Seiler S, De Koning JJ, Foster C. The fall and rise of the gender difference in elite anaerobic performance 1952–2006. Med Sci Sports Exerc. 2007;39(3):534–40.PubMedCrossRef
89.
Zurück zum Zitat Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–54.PubMedCrossRef Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–54.PubMedCrossRef
90.
Zurück zum Zitat Berthelot G, Tafflet M, El Helou N, et al. Athlete atypicity on the edge of human achievement: performances stagnate after the last peak, in 1988. PLoS One. 2010;5(1):e8800.PubMedCentralPubMedCrossRef Berthelot G, Tafflet M, El Helou N, et al. Athlete atypicity on the edge of human achievement: performances stagnate after the last peak, in 1988. PLoS One. 2010;5(1):e8800.PubMedCentralPubMedCrossRef
91.
Zurück zum Zitat Berthelot G, Thibault V, Tafflet M, et al. The citius end: world records progression announces the completion of a brief ultra-physiological quest. PLoS One. 2008;3(2):e1552.PubMedCentralPubMedCrossRef Berthelot G, Thibault V, Tafflet M, et al. The citius end: world records progression announces the completion of a brief ultra-physiological quest. PLoS One. 2008;3(2):e1552.PubMedCentralPubMedCrossRef
92.
Zurück zum Zitat Lippi G, Banfi G, Favaloro EJ, et al. Updates on improvement of human athletic performance: focus on world records in athletics. Br Med Bull. 2008;87:7–15.PubMedCrossRef Lippi G, Banfi G, Favaloro EJ, et al. Updates on improvement of human athletic performance: focus on world records in athletics. Br Med Bull. 2008;87:7–15.PubMedCrossRef
93.
Zurück zum Zitat Lodewijkx HF, Brouwer B. Some empirical notes on the epo epidemic in professional cycling. Res Q Exerc Sport. 2011;82(4):740–54.PubMedCrossRef Lodewijkx HF, Brouwer B. Some empirical notes on the epo epidemic in professional cycling. Res Q Exerc Sport. 2011;82(4):740–54.PubMedCrossRef
94.
Zurück zum Zitat El Helou N, Berthelot G, Thibault V, et al. Tour de France, Giro, Vuelta, and classic European races show a unique progression of road cycling speed in the last 20 years. J Sports Sci. 2010;28(7):789–96.PubMedCrossRef El Helou N, Berthelot G, Thibault V, et al. Tour de France, Giro, Vuelta, and classic European races show a unique progression of road cycling speed in the last 20 years. J Sports Sci. 2010;28(7):789–96.PubMedCrossRef
95.
Zurück zum Zitat Ernst S, Simon P. A quantitative approach for assessing significant improvements in elite sprint performance: has IGF-1 entered the arena? Drug Test Anal. 2013;5(6):384-9. Ernst S, Simon P. A quantitative approach for assessing significant improvements in elite sprint performance: has IGF-1 entered the arena? Drug Test Anal. 2013;5(6):384-9.
96.
Zurück zum Zitat De Rijckaert E. zaak Festina–Het recht van antwoord van dokter Eric Rijckaert [The Festina case—the right to an answer by doctor Eric Rijckaert]. Belgium: Uitgeverij Lannoo NV; 2000. De Rijckaert E. zaak Festina–Het recht van antwoord van dokter Eric Rijckaert [The Festina case—the right to an answer by doctor Eric Rijckaert]. Belgium: Uitgeverij Lannoo NV; 2000.
97.
Zurück zum Zitat Dekker T. Schoon genoeg [Clean enough]. Amsterdam: Arbeiderspers; 2011. Dekker T. Schoon genoeg [Clean enough]. Amsterdam: Arbeiderspers; 2011.
98.
Zurück zum Zitat Hamilton T, Coyle D. The secret race—inside the hidden world of the Tour de France: doping, cover-ups, and winning at all costs. USA: Bantam Books; 2012. Hamilton T, Coyle D. The secret race—inside the hidden world of the Tour de France: doping, cover-ups, and winning at all costs. USA: Bantam Books; 2012.
99.
Zurück zum Zitat Millar D, Whittle J. Racing through the dark. London: Orion Books; 2011. Millar D, Whittle J. Racing through the dark. London: Orion Books; 2011.
100.
Zurück zum Zitat Matschiner S, Behr M. Grenzwertig: Aus dem Leben eines Dopingdealers [Threshold-worthy: out of the life of a doping dealer]. Germany: Riva Sportverlag; 2011. Matschiner S, Behr M. Grenzwertig: Aus dem Leben eines Dopingdealers [Threshold-worthy: out of the life of a doping dealer]. Germany: Riva Sportverlag; 2011.
101.
Zurück zum Zitat Canseco J. Juiced: wild times, rampant’ roids, smash hits, and how baseball got big. USA: William Morrow; 2005. Canseco J. Juiced: wild times, rampant’ roids, smash hits, and how baseball got big. USA: William Morrow; 2005.
102.
Zurück zum Zitat Lentillon-Kaestner V, Carstairs C. Doping use among young elite cyclists: a qualitative psychosociological approach. Scand J Med Sci Sports. 2010;20(2):336–45.PubMedCrossRef Lentillon-Kaestner V, Carstairs C. Doping use among young elite cyclists: a qualitative psychosociological approach. Scand J Med Sci Sports. 2010;20(2):336–45.PubMedCrossRef
103.
Zurück zum Zitat Ohl F, Fincoeur B, Lentillon-Kaestner V, et al. The socialization of young cyclists and the culture of doping. Int Rev Sociol Sport. Epub 24 July 2013. Ohl F, Fincoeur B, Lentillon-Kaestner V, et al. The socialization of young cyclists and the culture of doping. Int Rev Sociol Sport. Epub 24 July 2013.
104.
Zurück zum Zitat Petroczi A, Mazanov J, Nepusz T, et al. Comfort in big numbers: does over-estimation of doping prevalence in others indicate self-involvement? J Occup Med Toxicol. 2008;3:19.PubMedCentralPubMedCrossRef Petroczi A, Mazanov J, Nepusz T, et al. Comfort in big numbers: does over-estimation of doping prevalence in others indicate self-involvement? J Occup Med Toxicol. 2008;3:19.PubMedCentralPubMedCrossRef
106.
Zurück zum Zitat Donovan RJ, Egger G, Kapernick V, et al. A conceptual framework for achieving performance enhancing drug compliance in sport. Sports Med. 2002;32(4):269–84.PubMedCrossRef Donovan RJ, Egger G, Kapernick V, et al. A conceptual framework for achieving performance enhancing drug compliance in sport. Sports Med. 2002;32(4):269–84.PubMedCrossRef
107.
Zurück zum Zitat Morente-Sanchez J, Zabala M. Doping in sport: a review of elite athletes’ attitudes, beliefs, and knowledge. Sports Med. 2013;43(6):395–411.PubMedCrossRef Morente-Sanchez J, Zabala M. Doping in sport: a review of elite athletes’ attitudes, beliefs, and knowledge. Sports Med. 2013;43(6):395–411.PubMedCrossRef
108.
Zurück zum Zitat Marclay F, Grata E, Perrenoud L, et al. A one-year monitoring of nicotine use in sport: frontier between potential performance enhancement and addiction issues. Forensic Sci Int. 2011;213(1–3):73–84.PubMedCrossRef Marclay F, Grata E, Perrenoud L, et al. A one-year monitoring of nicotine use in sport: frontier between potential performance enhancement and addiction issues. Forensic Sci Int. 2011;213(1–3):73–84.PubMedCrossRef
109.
Zurück zum Zitat Puffer JC. The use of drugs in swimming. Clin Sports Med. 1986;5(1):77–89.PubMed Puffer JC. The use of drugs in swimming. Clin Sports Med. 1986;5(1):77–89.PubMed
Metadaten
Titel
Prevalence of Doping Use in Elite Sports: A Review of Numbers and Methods
verfasst von
Olivier de Hon
Harm Kuipers
Maarten van Bottenburg
Publikationsdatum
01.01.2015
Verlag
Springer International Publishing
Erschienen in
Sports Medicine / Ausgabe 1/2015
Print ISSN: 0112-1642
Elektronische ISSN: 1179-2035
DOI
https://doi.org/10.1007/s40279-014-0247-x

Weitere Artikel der Ausgabe 1/2015

Sports Medicine 1/2015 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Traumatologische Notfälle Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.